BeiGene, Ltd. is a global biotechnology company engaged in discovering and developing oncology treatments for cancer patients worldwide. The Company has discovered and developed three approved medicines, including BRUKINSA, a small molecule inhibitor of Brutonâs Tyrosine Kinase for the treatment of various blood cancers; TEVIMBRA (tislelizumab), an anti-PD-1 antibody immunotherapy for the treatment of various solid tumor and blood cancers; and pamiparib, a selective small molecule inhibitor of poly ADP-ribose polymerase 1 (PARP1) and PARP2. The Company has obtained approvals to market BRUKINSA in the United States, the People's Republic of China (China or the PRC), the European Union, the United Kingdom, Canada, Australia, and additional international markets; tislelizumab in the European Union and China; and pamiparib in China. It also focuses on commercializing cancer medicines, such as XGEVA, BLINCYTO, KYPROLIS, and others in China under an exclusive license from Amgen Inc.

Employees

10,000

Sector

Biotechnology & Medical Research

Calendar

2024-11-06 - Q3 2024 Earnings Release (Projected)

More about the company

Quotes

Date	Price	Change	Volume
24-10-04	244.15 $	+4.50%	177,377
24-10-03	233.64 $	+0.02%	303,298
24-10-02	233.60 $	+1.13%	410,278
24-10-01	230.98 $	+2.88%	333,290
24-09-30	224.51 $	+2.79%	496,839

Delayed Quote Nasdaq, October 03, 2024 at 04:00 pm EDT

More quotes

Income Statement and Estimates

More financial data

Ratings

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

233.64USD

Average target price

274.14USD

Spread / Average Target

+17.33%

Consensus

Profit revisions

Estimate revisions

Quarterly earnings, Rate of surprise

Company calendar

Real-time Estimate Cboe BZX Other stock markets 10:56:21 2024-10-04 am EDT			5-day change	1st Jan Change
244.86 ^USD	+4.80%		+11.78%	+35.37%

03:29am	BeiGene Grants Options, Restricted Share Units to Employees	MT
Sep. 27	BeiGene Shares Climb Pre-Bell After FDA Gives Favorable Opinion on Class of Cancer Treatments	MT

Capitalization	24.87B	P/E ratio 2024 *	-39.3x	P/E ratio 2025 *	-266x
Enterprise value	23.15B	EV / Sales 2024 *	6.4x	EV / Sales 2025 *	5.15x
Free-Float	96.66%	Yield 2024 *	-	Yield 2025 *	-

BeiGene Grants Options, Restricted Share Units to Employees	09:29pm	MT
BeiGene Shares Climb Pre-Bell After FDA Gives Favorable Opinion on Class of Cancer Treatments	Sep. 27	MT
BeiGene, Ltd. Provides Update on FDA Advisory Committee Vote on Benefit-Risk Profile of PD-1 Inhibitors, Including TEVIMBRA®?, for Treatment of ESCC and Gastric/GEJ Cancers	Sep. 26	CI
BeiGene, Ltd. Appoints Shalini Sharp to Board of Directors and Member of the Audit Committee, Effective September 27, 2024	Sep. 26	CI
JMP Securities Initiates BeiGene at Outperform With $288 Price Target	Sep. 18	MT
BeiGene Receives Israeli Ministry of Health Approval for TEVIMBRA® for the Treatment of Oesophageal Squamous Cell Carcinoma After Prior Chemotherapy	Sep. 17	CI
Asian Equities Traded in the US as American Depositary Receipts Trend Higher in Thursday Trading	Sep. 12	MT
Asian Equities Traded in the US as American Depositary Receipts Decline in Wednesday Trading	Sep. 11	MT
BeiGene, Ltd. Presents at Morgan Stanley 22nd Annual Global Healthcare Conference, Sep-05-2024 10:00 AM	Sep. 05
BeiGene Grants Share Options, RSUs under Incentive Plan	Sep. 05	MT
BeiGene's H1 Loss Narrows as Revenue Rises	Aug. 26	MT
Sector Update: Health Care Stocks Higher Pre-Bell Monday	Aug. 26	MT
Sector Update: Health Care	Aug. 26	MT

JMP Securities Initiates BeiGene at Outperform With $288 Price Target	Sep. 18	MT
Nomura Adjusts BeiGene Price Target to $266 From $248.41, Maintains Buy Rating	Jul. 16	MT
Nomura Adjusts BeiGene's Price Target to HK$158.37 From HK$150, Keeps at Buy	Jul. 16	MT
BeiGene to Award Shares Worth $15 Million to 11 Directors	Apr. 17	MT
Bernstein Adjusts BeiGene's Price Target to $161 From $196, Maintains Market Perform Rating	Mar. 27	MT

BeiGene, Ltd. Stock

Equities

BGNE

US07725L1026

Biotechnology & Medical Research

Valuation: BeiGene, Ltd.

Chart: BeiGene, Ltd.

Latest news: BeiGene, Ltd.

Last Transcript: BeiGene, Ltd.

Analysts' recommendations: BeiGene, Ltd.

Press Releases: BeiGene, Ltd.

News in other languages: BeiGene, Ltd.

Quotes and Performance

Course Extremes

Managers and Directors: BeiGene, Ltd.

ETFs: BeiGene, Ltd.

Bio Therapeutic Drugs

Financials

Company Profile

Quotes

Income Statement and Estimates

Ratings

Analysts' Consensus

Quarterly earnings, Rate of surprise

Anbogen Announces Drug Supply Collaboration with BeiGene to Evaluate Combination Therapy in Colorectal Cancer	Sep. 30	AQ
BeiGene : A. Risk Factors Form 8 K	Sep. 30	PU
BeiGene Provides Update on FDA Advisory Committee Vote on Benefit-Risk Profile of PD-1 Inhibitors, including TEVIMBRA, for Treatment of ESCC and Gastric, GEJ Cancers	Sep. 27	AQ
BeiGene Provides Update on FDA Advisory Committee Vote on Benefit-Risk Profile of PD-1 Inhibitors, including TEVIMBRA®, for Treatment of ESCC and Gastric/GEJ Cancers	Sep. 26	BU
BeiGene : Global Oncology Innovator BeiGene Appoints Shalini Sharp to Board of Directors Form 8 K	Sep. 26	PU

Globaler Onkologie-Innovator BeiGene ernennt Shalini Sharp in sein Board of Directors	Sep. 26
BeiGene, innovador mundial en oncología, nombra a Shalini Sharp miembro del Consejo de Administración	Sep. 26
BeiGene, innovateur mondial en oncologie, nomme Shalini Sharp au conseil d'administration	Sep. 26
BeiGene präsentiert TEVIMBRA®-Daten bei Lungen- und Magen-Darm-Krebs auf dem ESMO 2024	Sep. 10
BeiGene présente les données de TEVIMBRA® sur les cancers pulmonaires et gastro-intestinaux au Congrès de l’ESMO 2024	Sep. 10

1 day	+0.02%
1 week	+9.93%
Current month	+4.07%
1 month	+24.10%
3 months	+57.89%
6 months	+53.76%
Current year	+29.54%

Director	Title	Age	Since
John Oyler CEO	Chief Executive Officer	56	10-10-27
Xiao Bin Wu PSD	President	62	18-03-31
Christiane Langer CTO	Chief Tech/Sci/R&D Officer	-	21-07-31

Name	Weight	AuM	1st Jan change	Investor Rating
LONCAR CHINA BIOPHARMA ETF - DISTRIBUTING - USD	2.48%	4 M€	-27.92%
LEVERAGE SHARES 3X LONG BIOTECHNOLOGY ETP SECURITIES - USD	1.49%	0 M€	0.00%	-
BAD ETF - USD	1.39%	9 M€	-4.31%	-

Add to a list Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5d. change	1-year change	3-years change	Capi. ($)
BEIGENE, LTD.	+0.02%	+9.93%	+34.09%	-34.50%	24.87B
VERTEX PHARMACEUTICALS INCORPORATED	-1.86%	-2.07%	+31.41%	+151.48%	117B
REGENERON PHARMACEUTICALS, INC.	-2.47%	-2.44%	+25.52%	+77.75%	110B
ARGENX SE	-3.79%	+0.31%	+5.42%	+87.29%	32.88B
BIONTECH SE	+0.67%	+1.84%	+9.58%	-52.98%	28.48B
WUXI APPTEC CO., LTD.	+10.00%	+21.01%	-39.24%	-65.73%	21.62B
GENMAB A/S	-0.72%	-3.02%	-35.40%	-42.23%	14.87B
SUMMIT THERAPEUTICS INC.	-4.76%	-18.41%	+951.41%	+264.19%	13.87B
VAXCYTE, INC.	-2.77%	-0.32%	+134.10%	+323.48%	13.74B
INSMED INCORPORATED	-2.22%	-2.02%	+193.59%	+160.77%	12.27B
Average	-0.23%	+1.92%	+131.05%	+86.95%	38.92B
Weighted average by Cap.	+0.31%	+1.97%	+61.19%	+89.38%

	2024 *	2025 *
Net sales	3.62B	4.54B
Net income	-673M	-158M
Net Debt	-1.72B	-1.51B